Stock JNJJOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Johnson & Johnson Stock

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:02 2025-05-16 EDT 		5-day change 1st Jan Change
151.33 USD +1.15% Intraday chart for Johnson & Johnson -1.87% +4.64%
05-18 British Regulator Approves Johnson & Johnson's Crohn's Disease Treatment MT
05-16 Sector Update: Health Care Stocks Rise Late Afternoon MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions on site

Valuation: Johnson & Johnson

Capitalization 364B 326B 305B 274B 509B 31,150B 569B 3,557B 1,391B 14,140B 1,366B 1,337B 52,938B P/E ratio 2025 *
14.5x
P/E ratio 2026 * 16.3x
Enterprise value 368B 330B 308B 278B 515B 31,521B 576B 3,599B 1,408B 14,308B 1,382B 1,353B 53,568B EV / Sales 2025 *
4.04x
EV / Sales 2026 * 3.76x
Free-Float
77.08%
Yield 2025 *
3.46%
Yield 2026 * 3.55%
More valuation ratios * Estimated data

Chart: Johnson & Johnson

Dynamic Chart

Latest news: Johnson & Johnson

British Regulator Approves Johnson & Johnson's Crohn's Disease Treatment 05-18 MT
Sector Update: Health Care Stocks Rise Late Afternoon 05-16 MT
Sector Update: Health Care Stocks Rise Friday Afternoon 05-16 MT
Sector Update: Health Care 05-16 MT
Johnson & Johnson Gets UK Regulatory Approval for Crohn's Disease, Ulcerative Colitis Drug 05-16 MT
Uk's MHRA Approved Guselkumab (Tremfya) To Treat Crohn'S Disease And Ulcerative Colitis 05-16 RE
France's Sanofi to invest at least $20 billion in US through 2030 05-14 RE
Roche says Trump's drug price order threatens its $50 billion US investment plans 05-14 RE
Exclusive-Vietnam cranks up fight on imported counterfeits amid US tariff talks 05-13 RE
Johnson & Johnson Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM 05-13
Leerink Partners Downgrades Johnson & Johnson to Market Perform From Outperform, $153 Price Target 05-13 MT
Equity Markets Higher After US-China Suspend Tariffs 05-12 MT
Sector Update: Health Care Stocks Climb Monday Afternoon 05-12 MT
More news

Last Transcript: Johnson & Johnson

Logo Johnson & Johnson
Johnson & Johnson Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM
05-13
More transcripts

Analysts' recommendations: Johnson & Johnson

Leerink Partners Downgrades Johnson & Johnson to Market Perform From Outperform, $153 Price Target 05-13 MT
Global markets live: Google, Microsoft, Coinbase, Boeing, IAG… 05-09Our Logo
Goldman Sachs Adjusts Price Target on Johnson & Johnson to $176 From $172, Maintains Buy Rating 05-02 MT
HSBC Adjusts Price Target on Johnson & Johnson to $184 From $180, Maintains Buy Rating 04-28 MT
Guggenheim Adjusts Price Target on Johnson & Johnson to $164 From $166, Keeps Neutral Rating 04-21 MT
More recommendations

Press Releases: Johnson & Johnson

Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails 05-15 BU
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 05-14 BU
Johnson & Johnson expands efforts to champion the nursing workforce globally; New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges 05-09 AQ
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis 05-09 PR
Johnson & Johnson expands efforts to champion the nursing workforce globally 05-08 BU
More press releases

News in other languages: Johnson & Johnson

J&J : présentera ses innovations cardiovasculaires à EuroPCR 05-15
Roche dice que decreto de Trump sobre medicamentos amenaza su inversión en EEUU 05-14
Prada, Gucci & Co: Vietnam will stärker gegen Fälschungen vorgehen 05-13
USA-Trump a signé un décret pour une réduction d'au moins 59% du prix des médicaments 05-12
Eli Lilly and : Apple, Fox, Eli Lilly... les valeurs à suivre aujourd'hui à Wall Street 05-12
More news

Quotes and Performance

1 day+1.15%
1 week-1.87%
Current month-3.19%
1 month-3.90%
3 months-3.09%
6 months-1.73%
Current year+4.64%
More quotes

Course Extremes

1 week 146.12
Extreme 146.115
 155.36
1 month 146.12
Extreme 146.115
 158.72
Current year 140.68
Extreme 140.68
 169.99
1 year 140.68
Extreme 140.68
 169.99
3 years 140.68
Extreme 140.68
 183.35
5 years 133.65
Extreme 133.65
 186.69
10 years 81.79
Extreme 81.79
 186.69
More quotes

Managers and Directors: Johnson & Johnson

Manager TitleAgeSince
Joaquin Duato CEO
 Chief Executive Officer 62 2022-01-02
Joseph Wolk DFI
 Director of Finance/CFO 58 2018-06-30
Penny M. Heaton CTO
 Chief Tech/Sci/R&D Officer 60 2024-07-31
Director TitleAgeSince
Anne Mulcahy BRD
 Director/Board Member 71 2009-10-22
Mark McClellan BRD
 Director/Board Member 61 2013-10-14
Mary Beckerle BRD
 Director/Board Member 70 2015-06-08
More insiders

ETFs: Johnson & Johnson

Name Weight AuM 1st Jan change
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
14.01% 378 M€ +2.81% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
12.91% 21 M€ -0.27% -
More ETFs: Johnson & Johnson

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
JOHNSON & JOHNSON Stock Johnson & Johnson
+1.15%-1.87%-2.14%-15.37% 364B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+3.50%+3.11%-1.64%+151.29% 680B
ABBVIE INC. Stock AbbVie Inc.
+1.29%-0.31%+10.58%+18.89% 325B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.81%-4.00%-52.78%+13.93% 283B
ROCHE HOLDING AG Stock Roche Holding AG
+1.05%+0.82%+9.53%-19.44% 248B
NOVARTIS AG Stock Novartis AG
+1.25%+0.62%-2.03%+4.64% 213B
ASTRAZENECA PLC Stock AstraZeneca PLC
+1.85%+0.88%-14.70%-1.51% 212B
MERCK & CO., INC. Stock Merck & Co., Inc.
+1.68%+0.12%-42.02%-18.22% 191B
AMGEN INC. Stock Amgen Inc.
+1.15%+2.46%-12.82%+11.03% 146B
PFIZER, INC. Stock Pfizer, Inc.
+1.02%+2.47%-20.29%-55.53% 130B
Average +1.21%+0.43%-12.83%+8.97% 279.29B
Weighted average by Cap. +1.52%+0.51%-9.71%+33.70%
See all sector performances

Financials

2025 *2026 *
Net sales 91.3B 81.72B 76.38B 68.78B 128B 7,811B 143B 892B 349B 3,545B 342B 335B 13,274B 95.03B 85.06B 79.51B 71.6B 133B 8,130B 148B 928B 363B 3,691B 356B 349B 13,817B
Net income 22.06B 19.75B 18.46B 16.62B 30.81B 1,887B 34.47B 216B 84.31B 857B 82.75B 81.03B 3,208B 22.2B 19.87B 18.57B 16.72B 31B 1,899B 34.68B 217B 84.83B 862B 83.26B 81.53B 3,227B
Net Debt 4.33B 3.88B 3.62B 3.26B 6.05B 370B 6.76B 42.29B 16.54B 168B 16.24B 15.9B 629B -6.45B -5.77B -5.4B -4.86B -9.01B -552B -10.08B -63.01B -24.65B -251B -24.2B -23.69B -938B
More financial data * Estimated data

Company Profile

Logo Johnson & Johnson
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.
Employees
138,100
Sector
Pharmaceuticals
Calendar
05-20 - RBC Global Healthcare Conference - Fireside Chat
More about the company

Quotes

Date Price Change Volume
25-05-16 151.33 $ +1.15% 8,051,150
25-05-15 149.61 $ +2.22% 7,945,768
25-05-14 146.36 $ -1.40% 10,215,952
25-05-13 148.44 $ -3.70% 10,549,609
25-05-12 154.14 $ -0.05% 9,023,782

Delayed Quote Nyse, May 16, 2025 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
151.33USD
Average target price
169.18USD
Spread / Average Target
+11.80%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. JNJ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition